Die US-Investmentbank Goldman Sachs hat Novartis CH0012005267 von "Neutral" auf "Sell" abgestuft und das Kursziel von 95 auf 94 Franken gesenkt.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.